<DOC>
	<DOCNO>NCT01549470</DOCNO>
	<brief_summary>Currently , vaccine prevents HIV infection . This study test safety immune response HIV-1 DNA vaccine HIV-uninfected adult Ugandan population .</brief_summary>
	<brief_title>Evaluating Safety Immune Response HIV Vaccine Healthy , HIV-Uninfected Adults Uganda</brief_title>
	<detailed_description>The global HIV/AIDS epidemic continue increase unacceptably high level , yet effective prevention method HIV infection . This study test safety immune response preventive HIV vaccine , VRC-HIVDNA009-00-VP , multiclade HIV-1 DNA plasmid vaccine . This study seek enroll 30 participant , randomly assign 15 participant study vaccine arm placebo vaccine arm . Three dos vaccine give intramuscular ( IM ) injection use Biojector 2000 needle-free injection management system : first dose Day 0 ( entry ) , second dose Day 28 ( within 7 day Day 28 ) , third dose Day 56 ( within 7 day Day 56 ) . Participants attend two screen visit visit Days 0 ( entry ) , 2 , 14 , 28 , 30 , 42 , 56 , 58 , 70 , 84 , 168 , 252 , 336 . At visit , participant give medical history undergo physical exam , blood draw , urine collection . For woman , pregnancy test give study injection visit . Participants also instruct maintain diary local systemic reaction 7 day injection . They also provide ruler measure erythema , induration , observable reaction thermometer record temperature daily basis .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : 18 40 year old Available followup duration study ( 13 month ) Satisfactory completion Assessment Understanding prior enrollment define 90 % correct three opportunity take test . Errors review volunteer test . Able willing sign inform consent form Willing receive HIV counsel test accordance Ugandan Ministry Health Guidelines Willing discus HIV infection risk currently highrisk HIV define response standard questionnaire find protocol , agree engage highrisk behavior HIV study define protocol , amenable riskreduction counsel Willing permit home visit one two screen visit In good general health without clinically significant medical history Physical examination laboratory result without clinically significant finding within 45 day prior first injection Can understand read English Luganda Within 45 day prior enrollment , must meet following criterion : Hemoglobin great 11.0 g/dL woman 12.5 g/dL men White blood cell ( WBC ) count : 3,300 12,000 cells/mm^3 ( absence clinical pathological etiology ) Differential either within institutional normal range accompany site physician approval . More information criterion find protocol . Total lymphocyte count great 800 cells/mm^3 ( absence clinical pathological etiology ) Platelets = 125,000 550,000 cells/mm^3 Alanine aminotransferase ( ALT ) ( serum glutamic pyruvic transaminase [ SGPT ] ) less 1.25 time upper limit normal ( ULN ) Serum creatinine less ULN Normal urinalysis define dipstick negative glucose , negative trace protein , negative trace hemoglobin ( blood ) Negative Food Drug Administration ( FDA ) approve HIV blood test Negative serum hepatitis B surface antigen test Negative serum hepatitis C antibody test Negative urine serumhuman chorionic gonadotropin ( HCG ) pregnancy test woman . A female participant must meet one follow criterion 21 day prior vaccination 3 month follow last vaccination : 1 . No reproductive potential hysterectomy , bilateral oophorectomy , tubal ligation . Documentation qualify medical doctor must obtain confirmation procedure , OR 2 . Participant agree consistently practice contraception least 21 day prior vaccination throughout duration study one follow method : 1. condom , male female , without spermicide 2. diaphragm cervical cap spermicide 3. intrauterine device 4. contraceptive pill , Norplant DepoProvera 5. male partner previously undergone vasectomy documentation 6. abstinence sexual activity Men take part study plan father child first vaccination 3 month last vaccination . Men consistently use condom , provide documentation vasectomy qualify medical doctor , practice abstinence sexual activity , OR female partner use one follow method : 1. female condom , without spermicide 2. diaphragm cervical cap spermicide 3. intrauterine device 4. contraceptive pill , Norplant DepoProvera Exclusion Criteria Woman breastfeeding Has receive HIV vaccine prior clinical trial Has receive immunosuppressive cytotoxic medication within past 6 month exception corticosteroid nasal spray allergic rhinitis topical corticosteroid acute uncomplicated dermatitis Has receive blood product within 120 day prior HIV screening Has receive immunoglobulin within 60 day prior HIV screening Has receive live attenuate vaccine within 30 day prior initial study vaccine administration Has receive investigational research agent within 30 day prior initial study vaccine administration Has receive medically indicate subunit kill vaccine , e.g . influenza , pneumococcal , allergy treatment antigen injection , within 14 day study vaccine administration Is receive current antituberculosis ( TB ) prophylaxis therapy History serious adverse reaction vaccine anaphylaxis , hive , respiratory difficulty , angioedema , abdominal pain History autoimmune disease immunodeficiency History asthma unstable require emergent care , urgent care , hospitalization , intubation past 2 year require use oral intravenous corticosteroid History diabetes mellitus ( type I II ) , exception gestational diabetes History thyroid disease include history thyroidectomy diagnose require medication within past 12 month History serious angioedema episode within previous 3 year require medication previous 2 year History hypertension control medication 140/90 enrollment History bleed disorder diagnose doctor ( e.g. , factor deficiency , coagulopathy , platelet disorder require special precaution ) significant bruise bleed difficulty IM injection blood draws History active syphilis document exam serology unless positive serology due remote ( great 6 month ) treat infection positive rapid plasma reagin ( RPR ) /venereal disease research laboratory ( VDRL ) associate positive treponemal specific serology History malignancy active treated malignancy reasonable assurance sustain cure malignancy likely recur period study History seizure disorder febrile seizures age 2 , seizure secondary alcohol withdrawal 3 year ago , singular seizure require prolong treatment 3 year ago History asplenia condition result absence removal spleen History psychiatric condition precludes compliance protocol , past present psychosis , past present bipolar disorder suicidal ideation History medical , psychiatric , social condition occupational responsibility , judgment investigator , would interfere serve contraindication protocol adherence volunteer 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>